95 related articles for article (PubMed ID: 19681894)
1. Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Ozawa A; Tanji N; Kikugawa T; Sasaki T; Yanagihara Y; Miura N; Yokoyama M
BJU Int; 2010 Apr; 105(8):1181-6. PubMed ID: 19681894
[TBL] [Abstract][Full Text] [Related]
2. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Wei M; Wanibuchi H; Morimura K; Salim EI; Moku M; Doi K; Mitsuhashi M; Masuda C; Shen J; Kinoshita A; Fukushima S
Anticancer Res; 2004; 24(2B):785-90. PubMed ID: 15161027
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
5. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
6. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest.
Li GC; Zhang X; Pan TJ; Chen Z; Ye ZQ
Int J Urol; 2006 May; 13(5):581-6. PubMed ID: 16771729
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
[TBL] [Abstract][Full Text] [Related]
9. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
11. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
12. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo.
Mannaerts I; Nuytten NR; Rogiers V; Vanderkerken K; van Grunsven LA; Geerts A
Hepatology; 2010 Feb; 51(2):603-14. PubMed ID: 19957378
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
16. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
17. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo.
Lee SJ; Cho YH; Park K; Kim EJ; Kang BS; Jung KH; Kim CH; Kim WJ; Moon SK
Phytother Res; 2009 Jan; 23(1):20-7. PubMed ID: 19048611
[TBL] [Abstract][Full Text] [Related]
19. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition.
Michaelis M; Suhan T; Reinisch A; Reisenauer A; Fleckenstein C; Eikel D; Gümbel H; Doerr HW; Nau H; Cinatl J
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3451-7. PubMed ID: 16123451
[TBL] [Abstract][Full Text] [Related]
20. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.
Boorjian S; Tickoo SK; Mongan NP; Yu H; Bok D; Rando RR; Nanus DM; Scherr DS; Gudas LJ
Clin Cancer Res; 2004 May; 10(10):3429-37. PubMed ID: 15161698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
